Expression of c-Myc is highly prevalent in human breast cancer and stability of the oncoprotein is regulated through Ras-regulated phosphorylation at serine 62 and threonine 58. Previous studies have illustrated the importance of accumulation of KRas mutations in Myc-mediated tumor formation. To examine Myc dependence upon Ras mutations we have generated MMTV regulated Myc and Myc T58A transgenic mice. Expression of the more stable T58A Myc allele resulted in a reduction in KRas-activating mutations. However, in a low-level expression T58A Myc transgenic, the majority of the tumors were squamous or epithelial-to-mesenchymal in nature and accumulated KRas mutations at a higher frequency. Interestingly, we show that these mice develop similar gene expression patterns and signaling pathway utilization as a subtype of human claudin-low breast cancer. Indeed, our results demonstrate a clear division in human claudin-low tumors based on Myc pathway activation and target genes. Together, our results demonstrate that Myc expression and stability has critical effects on molecular heterogeneity in mouse mammary tumors that parallel subtypes of human breast cancer.
INTRODUCTION
Human breast cancer is a collection of remarkably diverse neoplasms. The combination and context of the events that initiate transformation lead to varied regulation of cellular processes and give rise to tumor heterogeneity. This is reflected in gene expression, allowing the categorization of tumors into molecular subtypes. [1] [2] [3] In addition, these molecular subtypes of breast cancer differ in terms of differentiation, response to therapy and overall survival. 4 For some subtypes, associations have been made with specific oncogene activity. For example, the basal molecular subtype has been associated with high expression of the Myc oncogene. 5 Myc is amplified in 15% of human breast cancers 6 and the degree of Myc amplification has been shown to correlate with mRNA levels and protein levels of Myc. 7 Moreover, when large cohorts of human breast cancers were examined for Myc pathway activation, nearly 25% of the tumors showed a high probability of Myc signal activation, 8, 9 correlating with previous reports. 10, 11 The half life of Myc is brief and the stability of Myc is regulated by phosphorylation events at key serine and tyrosine sites. 12, 13 The first phosphorylation event is mediated by Ras signaling through Erk, leading to phosphorylation at Ser62. This stabilizes Myc and allows subsequent phosphorylation by GSK3b at Thr58, targeting Myc for ubiquitination. This GSK3b phosphorylation event may be blocked through Ras activation of PI3K/AKT, extending the half life of Myc. The active Ser62 phosphorylated Myc initiates transcription by forming heterodimers with the Max transcription factor.
14 Once activated, Myc has been demonstrated to regulate a wide range of transcriptional targets. 15 Thus, Myc initiated changes in gene expression have a variety of effects resulting in the formation of breast cancer.
Myc effects on mammary development and cancer has been examined through mouse models. Myc was initially overexpressed in the mouse mammary gland using the MMTV promoter, resulting in the formation of adenocarcinomas. 16 The importance of Ras in these tumors was demonstrated by the synergistic reduction in tumor latency observed by interbreeding MMTV-Myc and MMTVRas transgenic mice. 17 Additionally, in a conditional Myc model, KRas mutations were detected with Myc withdrawal, correlating with tumor progression and recurrence. 18 Subsequently, a synergy with KRas was detected in Myc-initiated tumors where Ras was seen to be a more dominant oncogene. 19 In recent work, a knock-in approach to overexpress Myc at low levels demonstrated that decreased stability of Myc by S62A mutation abrogated Myc's transformation ability. In contrast, a T58A mutation enhanced the formation of tumors. 20 However, the majority of mice in this study developed brain tumors, preventing examination of T58A Myc in breast cancer. Taken together, these mouse models illustrate the role of Myc in mediating breast cancer and the importance of the Ras pathway in this process.
In previous work, we demonstrated that Myc expression affected tumor heterogeneity at the genomic and histological level. 21 In light of these results, we hypothesized that a stabilizing T58A mutation in Myc would decrease the dependence upon activating mutations in KRas for tumorigenesis. To test this hypothesis, Myc and Myc T58A transgenic mice were generated. We noted a decrease in activating mutations in KRas in Myc T58A strains with high levels of Myc expression. Through comparative gene expression analysis, we established similarities between the EMT-type (EMT, epithelial-to-mesenchymal transition) T58A Myc tumors and human claudin-low breast cancer.
RESULTS

Mouse model characterization
Mammary tumors initiated by Myc in transgenic mice result in the accumulation of activating mutations in KRas. We hypothesized that tumor formation in transgenic mice with a stabilizing T58A version of Myc would not be dependent upon accumulation of activating mutations in KRas. To test this hypothesis we generated Myc transgenic mice with the constructs shown in Figure 1a . For the wild-type (WT) Myc transgenics, a total of four lines were generated and T58A resulted in an additional 11 lines. A RNase protection assay was completed in virgin and lactating mice to assess transgene expression (Figure 1b) . This revealed that two WT Myc lines (WT13 and WT21) were expressing the transgene at a high level in the virgin mammary gland with a significant increase in expression levels in the lactating samples. In the T58A Myc genotype, two lines were noted to have comparable levels of transgene expression (TA14 and TA41). In addition, we retained TA39 transgenic mice to assay for effects of Myc expressed at lower levels. We also assessed mammary glands for both HA-Myc (Figures 1c and d) and total Myc protein ( Supplementary Figures  1a and c) levels. Western blot results show that the T58A mutation stabilized Myc in the mammary gland. This resulted in higher protein levels of HA-Myc in the mammary gland given similar levels of mRNA when comparing the T58A to the WT transgenic lines (P ¼ 0.007). In addition, we quantified total Myc levels in the mammary glands of non-transgenic FVB mice to assess the degree of protein overexpression in the T58A transgenic lines, demonstrating at least 3.5 fold more total Myc protein in the transgenic mice compared with non-transgenic FVB mice ( Supplementary  Figures 1e and f) .
To determine the initial effect of the transgene expression on mammary gland development in these lines, whole mounts of the mammary glands were assessed at 8 weeks of development. In comparison with the WT control (Figure 1e ), we assessed the WT13, WT21, TA14, TA41 and TA39 lines (Figure 1f -j, respectively). This revealed that the lines with elevated transcript levels had abnormal side bud formation in comparison with the WT control. The most prominent alterations were noted in the two strains with high levels of Myc expression, WT13 and TA14, noted with arrowheads relative to the control in Figure 1e , f and h. In addition, the low-expressing TA39 transgene had minimal phenotypic affects on mammary development.
To determine the effects of the T58A mutation on tumor latency, females from the five lines were maintained in a constant breeding program. We observed a large number of mice for each strain including; WT13 n ¼ 70, WT21 n ¼ 49, TA14 n ¼ 60, TA41 n ¼ 52 and TA39 n ¼ 62. Surprisingly, there was no difference in tumor latency between the high level of expression Myc or Myc T58A strains (Figure 2a ). However, we did note a significant increase in tumor latency for the low-expressing Myc T58ATA39 strain (Po0.001 relative to WT and Po0.0001 relative to the other T58A strains). Measuring the number of tumors in each mouse revealed no difference between the WT MMTV-Myc and high expressing T58A Myc transgenics (Figure 2b) . Consistent with the tumor latency effects we noted that there was a reduction in tumor burden in the TA39 line with the majority of mice harboring a single tumor ( Figure 2b ) (P ¼ 0.0002 compared with WT and 0.0005 compared with T58A high).
Reduced KRas mutation in T58A tumors To ascertain whether T58A mutations reduced the frequency of activating mutations in KRas, we sequenced for KRas-activating mutations at codons 12, 13 and 61. An example of a WT sequence trace for codons 12 and 13 is shown in Figure 3a . In contrast, a sequence trace harboring a heterozygous mutation in codon 12 is shown (Figure 3b ). Of note is that heterozygosity has been preserved in 59 of the 61 tumors containing activating mutations in KRas. We then compared the KRas activation in the five transgenic lines. KRas mutations were observed in 22.4 and 25.6% in the two WT Myc lines (n ¼ 24 mutant KRas alleles for 107 tumors Figure 1 . Generation of Myc and Myc T58A transgenic mouse models. The construct to generate transgenic mice consist of Myc cDNA or Myc T58A placed under the transcriptional control of the MMTV promoter enhancer and is followed by a HA tag and a SV40 polyadenylation sequence (a). RNase protection assay for transgene expression in both 8 week virgin (v) and lactating (l) mammary glands is shown for the SV40 polyA signal with a PGK internal control (b). Western blot analysis for Myc and Grb2 from mammary glands from the various strains is shown (c). Standardization of Myc protein levels to the Grb2 control show Myc protein levels was completed (d). Mammary gland whole mounts in comparison with the WT control (e) are shown for WT13, WT21, TA14, TA41 and TA39 lines at 8 weeks of age (f-j, respectively). Differences in side bud formation relative to WT control (e) in the WT13 (f) and TA14 (h) strains are highlighted with arrowheads. in WT13 and 10 mutations for 39 tumors in WT21) (Figure 3c) . A T58A mutation in Myc significantly lowered the percentage of tumors containing an activating mutation with rates of 14.6 and 16.1% in the T58A high expressing lines (n ¼ 13 mutations in 89 tumors for TA14 and 11 mutations in 68 tumors for TA41) (P ¼ 0.042 by Fisher's two tailed t-test). Interestingly, there was an increase in the number of mutations observed in the lowexpressing TA39 line relative to the high expressing lines with 22.2% of tumor-bearing mutations (n ¼ 27 tumors). Together this data suggest that the T58A mutation reduces the dependence upon accumulation of KRas mutations. However, the WT transgenic line mutation rate does not concur with previously published data for Ras mutations in the WT strain where 44% of MMTV-Myc tumors were found to have Ras mutations. 18 To investigate this, we examined 21 of the original MMTV-Myc strain tumors and found 11 activating mutations in KRas, equal to 52% of tumors with mutations. To examine the difference between our MMTV-Myc WT13 line (22.4% mutation rate) and the original MMTV-Myc (52% mutation rate), we measured transgene levels through QRT-PCR. This revealed that Myc expression was nearly fourfold higher in lactating mammary gland of the WT13 line compared with original MMTV-Myc mice. (Supplementary Figure 2a) . Thus, we find a reduction in KRas mutation rates To examine whether the generation of an activating mutation in KRas was associated with alterations to latency, transgenic mice with and without activating mutations were compared. For WT MMTV-Myc lines, we observed a significant reduction in latency for mice with tumors containing a KRas mutation relative to mice with tumors without a mutation (P ¼ 0.0384) (Figure 3d ). Interestingly, the latency acceleration due to KRas mutations was not observed in the T58A lines with high levels of Myc expression (Figure 3e ). To compare these mouse mutations to human breast cancer, the COSMIC database was searched for breast cancers with mutations in KRas. Interestingly, the mouse tumors and human breast cancers shared the same pattern of KRas mutations with a range of mutation types in the mice (Supplementary Figure 3 and  Supplementary Table 1 ).
Genomic characterization of T58A tumors We previously demonstrated that there was significant heterogeneity in the development of tumors in a subset of Myc and Myc T58A lines (WT13, WT21, TA14 and TA41). 21 To assess the KRas mutation status in the heterogeneous tumors, we examined the KRas mutation rate in the various histological subtypes of tumors, grouped into WT, T58A high and T58A low-expressing strains ( Figure 3f ) and individually (Supplementary Figure 4) . This revealed that the vast majority of tumor types, and all transgenic lines, had tumors with activating mutations in KRas (Figure 3f ). However, we noted an elevation in the frequency of activating mutations in KRas in the EMT subtype of tumors. Moreover, the majority of the tumors in the low-expressing TA39 T58A transgenics were either squamous or EMT in nature.
We then assayed gene expression for the low-expressing T58A tumors in relation to the gene expression data from the other Myc samples. 21 After batch effects were removed (Supplementary Figure 5) , unsupervised hierarchical clustering showed that differences in tumor histology are reflected in gene expression. It is important to note that the number of tumors analyzed by microarray is not proportional to the number of tumors in each class. However, the addition of new gene expression data from TA39 transgenic refined prior clustering analysis and allowed the separation of EMT tumors and squamous tumors (Figures 4a and  b) . In addition, we observed that the majority of tumors clustered into the subtypes predicted by their histological classifications (Figure 4b ). Cell signaling pathway signatures were applied to the entire data set with the samples maintained in the order established through unsupervised clustering (Figure 4c ). This revealed patterns of signaling pathway activation associated with the various histological subtypes. Importantly, the distinction between the EMT and Squamous subtypes noted in unsupervised clustering was maintained and we noted significant differences between these subtypes in RhoA, AKT, p63, E2F1 and b-catenin pathways (Figure 4c and Supplementary Figure 6 ). Importantly, we predicted a low probability of Myc signaling in tumors of the EMT histology compared with microacinar and papillary tumors. To validate the genomic data, tumors from the various subtypes and transgenic lines were assessed for levels of Myc. This revealed that the EMT tumors had significantly lower levels of Myc expression (Figure 4d, Supplementary Figure 7) . Quantification of this result supported these findings (Figure 4e, Supplementary Figure 8) . Confirming the accuracy of our gene signature approach, probability values for Myc activation show a positive correlation with western blot quantification of total and exogenous Myc levels in corresponding tumor samples (Supplementary Figure 9) .
As noted above, when the Myc transgenic tumors were examined for activation of the Myc pathway, we observed variable levels of Myc activation in the various subtypes (Figure 4c ). We hypothesized that this difference in predicted Myc signaling would result in differential activation of Myc target genes. To test this hypothesis we analyzed expression levels of Myc target genes using previously published ChIP-chip data to identify Myc target genes. 15 In addition, by using Significance Analysis of Microarrays 22 we identified genes that were upregulated in human mammary epithelial cells that overexpress Myc relative to controls. 23 A Venn Diagram reveals that of the 118 genes identified, only 31 were Myc targets (Figure 5a ). Subsequently, we compared gene expression between samples from each histological cluster. In this analysis, we found 1958 significantly upregulated genes, of which 110 were Myc targets. Together, these results indicate that there is differential expression of Myc transcriptional targets in histological subtypes (Figure 5a ). To visualize the difference in activation of Myc target genes we extracted Myc targets as identified by Chip-Chip from the Myc tumor gene expression data for Significance Analysis of Microarrays analysis. By minimizing the false discovery rate and ranking genes on fold change, we identified the top 70 differentially regulated genes within each histological cluster. By using these 280 genes in unsupervised hierarchical clustering, we illustrated that tumors extracted from the histological clusters defined in Figure 4 differentially activate unique Myc target genes (Figure 5b ). Comparisons with human breast cancer To compare these mouse models with human breast cancer we combined our mouse gene expression data with human breast cancer gene expression data after removing batch and platform effects (Supplementary Figure 10) . Through unsupervised hierarchical clustering, we compared Myc-mediated mouse mammary tumors and subtypes of human breast cancer that were annotated with the intrinsic classification. 2, 4 This revealed that Myc tumors with microacinar histology clustered with a subset of human luminal B tumors (Figure 6a ). In addition, we observed that EMT subtype of Myc mouse tumors clustered with a subset of human claudin-low tumors. These EMT-type tumors with similarities to claudin-low tumors were found in both the WT and T58A strains (Supplementary Figure 11) , although the TA39 strain did have a greater percentage of tumors with the EMT histological pattern (Figure 3f) . Importantly, this clustering approach split the claudinlow tumor subtype into two distinct groups. When we assessed Myc targets for gene expression in the listed genes we observed a significant decrease in expression levels of Myc targets in the human breast cancer claudin-low samples clustered with the EMT samples relative to the other main cluster of claudin-low human breast cancers (Fisher's exact Po0.001). A comparison of marker expression levels between EMT-type tumors and other types of Myc-induced tumors shows that the EMT subtype largely parallels human claudin-low tumors (Supplementary Figure 12) . For example, EMT mouse tumors show low expression of cell-cell adhesion genes characteristic of human claudin-low tumors (Figure 6b, Supplementary Figure 12) . Like claudin-low tumors, Myc-induced EMT tumors show high expression of the mesenchymal marker vimentin, as well as the angiogenesis marker VEGFC (Figure 6b) , as well as other markers of claudin-low tumors (Supplementary Figure 12) . Importantly, we noted a difference in Myc target expression levels in these claudin-low tumors, split into two clusters. In agreement with this result, these two clusters of claudin-low tumors also significantly differed in predicted Myc signal pathway activation (Figure 6c) . As a result, we define these two subclasses of human claudin-low tumors on the basis of Myc activity: the Myc-low claudin-low tumors and the Myc-high claudin-low tumors.
In addition, previous work has shown that claudin-low tumors have stem cell-like characteristics. 24 Given the gene expression similarities between the mouse EMT-type tumors and the human Myc-low claudin-low tumors, we hypothesized that the mouse EMT type of tumors also have stem cell-like characteristics. To test this hypothesis we utilized Gene Set Enrichment Analysis and employed two gene sets derived from previously published gene expression data from mammary stem cells. 25 By comparing EMT type with the remaining histologies of Myc-induced tumors, we found that the EMT type of tumors are significantly enriched (P ¼ 0.021) for expression of genes that are upregulated in mammary stem cells (Supplementary Figure 13a) . Likewise, EMTtype Myc-induced tumors are significantly enriched (Po0.0001) with low expression of genes that are downregulated in mammary stem cells (Supplementary Figure 13b) . Together, these results show that the EMT type of Myc tumors match human claudin-low tumors for expression of claudin-low markers and features of stem cells.
In comparing the EMT-type Myc-initiated tumors to the Myc-low claudin-low human breast cancers, we also noted significant similarities at the pathway activation level (Figure 6c) . AKT, b-catenin, E2F1, Myc and p110 pathways are predicted to have low activity in EMT and the Myc-low claudin-low tumors while TNF-alpha signaling is similarly activated in these two tumors types. These same pathways are predicted to have significantly different activity between the Myc-low claudin-low tumors from the claudin-low tumors that did not cluster with the mouse tumors (Figure 6c, Supplementary Figure 14) . In a similar experiment for microacinar tumors, we revealed that similar activation patterns of the b-catenin and Stat3 pathways occur between the mouse and largely luminal B human breast cancers within the cluster (Figure 6d ). In addition, these pathways distinguish the microacinar-like luminal B tumors from other luminal B tumors where b-catenin is predicted to a significantly lower activity and Stat3 is predicted to have a significantly higher activity (Figure 6d,  Supplementary Figure 15) . Taken together, these data reveal that there are striking similarities between subtypes of Myc-induced mouse tumors and subsets of primary human breast cancers.
Given the molecular similarities between the EMT type of mouse mammary tumors and human claudin-low tumors, we sought to determine whether the results for KRas mutations in the EMT type of mouse mammary tumors also extended to human claudin-low breast cancer. KRas mutations occur in 3% of breast cancers contained within the COSMIC database. However, the molecular subtype of the primary tumors with these mutations is not reported, precluding an examination of Ras mutation status in subtypes. Alternatively, we predicted the probability of Ras signal pathway activation in human breast tumors. We find that nearly 80% of the claudin-low tumors predict an elevation in Ras signaling activity (Supplementary Figure 16) . This may indicate that KRas mutations occur more frequently in claudin-low tumors, similar to EMT tumors in the MMTV-Myc mouse model. To further establish the significance of KRas mutations to the human claudinlow tumors and the EMT type of MMTV-Myc-initiated tumors they are tightly correlated with, we used Gene Set Enrichment Analysis and a signature for KRas addiction. 26 A comparison between KRas mutant EMT-type tumors and all other KRas mutant mouse mammary tumors showed that although MMTV-Myc EMT type of tumors develop KRas mutations, they have a low probability of dependence upon this mutation for tumorigenesis ( Supplementary  Figure 17a) . Likewise, claudin-low tumors, compared with human basal tumors, which also feature high levels of predicted Ras signaling, also predict low probability of KRas addiction (Supplementary Figure 17b) . This is in agreement with the previously published work that shows that KRas mutant tumors with a mesenchymal phenotype are not dependent upon KRas signaling during tumorigenesis. 26 Together, these data show a clear link between the Ras mutation findings in the mouse model EMT tumors and the claudin-low subtype.
DISCUSSION
Here, we have characterized mammary gland development in T58A transgenic mice and observed mammary gland effects that correlate with elevated Myc expression. The increased side bud formation we see in mice with high Myc expression is similar to mammary gland effects in other studies featuring elevated Myc. 18, 27 Although no mammary effects were observed in the TA39 line at these early time points, all strains developed mammary tumors. Surprisingly, the tumor onset in the high expressing WT and T58A strains was virtually identical with a delay observed in the TA39 strain. We had anticipated that the increased Myc stability would result in more rapid tumor onset. A possible explanation for the similarities in tumor onset between the T58A and WT strains is that signaling conditions during the time when the MMTV promoter is most active, facilitate phosphorylation of S62 in the WT Myc strains, mimicking a T58A mutation under these circumstances.
Our hypothesis that an increase in Myc stability through T58A mutation would result in a reduction in dependence upon KRas mutations was validated. We observed a 1.5-fold reduction in the number of KRas-activating mutations in the T58A lines relative to the WT Myc transgenic lines. In addition, we observed that tumors with the lowest levels of Myc protein, tumors with an EMT histology, also had the highest frequency of KRas mutations. Moreover, there was a selective advantage in the WT mice that accumulated KRas mutations that was absent in the T58A strain. When our WT Myc transgenic mice are compared with previous studies with Myc mouse models, we note that our lines have far fewer KRas mutations, but this can be attributed to the lower levels of Myc in the previously characterized Myc strain. 16 However, the original Myc mice have equivalent Myc transcription to the T58A strains, demonstrating a far more impressive reduction in the requirement for activating KRas mutations with the stable T58A form of Myc. Yet, by comparison with WT strains, it was not readily apparent that T58A tumors expressed higher levels of Myc. This suggests that the possibility the T58A mutation may extend influence beyond Myc levels and KRas mutation rates. This hypothesis is reinforced by the distinct pathology of Myc-induced tumors as tumors from T58A strains exhibit primarily a papillary histology.
Amongst the histological clusters, we noted diverse probability of activation of the Myc-signaling pathway. We hypothesized that this difference would result in differential activation of Myc target genes in the different subtypes. Interestingly, we note that tumors with differences in histology and Myc stability also have differences in Myc target utilization. This suggests that differences in Myc expression and stability influence divergent tumor histologies by differential activation of direct Myc targets. We also noted variability in Myc pathway activation in human breast cancer samples. Although HER2 and luminal subtypes show sporadic activation of Myc signaling, we see that basal and a subset of claudin-low tumors are predicted to have high activation of the Myc-signaling pathway. In agreement with this, we noted high expression of a cluster of genes made up of mainly Myc targets in this subtype. Illustrating the validity of our approach, other studies have established that Myc is highly expressed in basal tumors. 5 Together, this data suggest that Myc may have a role influencing tumor heterogeneity both in mouse and human breast cancers.
Mouse models have been compared with human breast cancer through histology, signaling pathway activation and through genomic means. 28 In addition, recent work has identified a p53 mutant mouse model with similarities to the claudin-low subtype. 24 However, our work is unique in that we have stratified human claudin-low tumors into two subclasses based on Myc expression levels. With these results, we report remarkable similarities between the EMT type of Myc-induced tumors and human claudin-low tumors. Not only do we identify a correspondence in gene expression and signal pathway activation between EMT-type tumors and Myc-low claudin-low tumors, but we also show that EMT tumors match claudin-low tumors for stem cell characteristics and expression patterns of markers for claudin-low tumors. Along with expression patterns for markers cell-cell adhesion, we show EMT-type tumors match human claudin-low tumors for high expression of mesenchymal markers. This mesenchymal identity may be critical to the understanding of the significance of KRas mutations or increased Ras signaling in both the mouse model EMT-type tumors and the human claudin-low tumors. Previous work has shown that KRas mutant epithelial tumors are addicted to KRas, whereas KRas mutant mesenchymal tumors are not dependent upon KRas for tumor proliferation. 26 Using a gene signature for KRas derived from this study, we used Gene Set Enrichment Analysis to predict whether the claudin-low tumors and KRas mutant EMT-type tumors were independent of KRas. Consistent with their mesenchymal identities, both the human claudin-low tumors and the mouse model tumors are not predicted to be 'KRas addicted'. It is important to note that the mouse model EMT tumors that clustered with the Myc-low claudin-low tumors were found in all strains (Supplementary Figure 11) . This suggests that the presence of EMT, and not a T58A mutation, drives the similarities between mouse model EMT tumors and claudin-low tumors. Furthermore, with the human claudin-low tumors split on the basis of Myc signaling, the low levels of Myc, along with the presence EMT, found in the mouse model EMT tumors likely drive the similarities to Myc-low human claudin-low subclass. Taken together, these data suggest that the EMT subtypes of the Myc transgenic mice are a model for human claudin-low breast cancer.
Overall, our results show the importance of Myc stability and expression in mammary gland development and tumorigenesis. We show that differences in oncogene expression and stability can significantly alter molecular features of mammary tumors. The reduced dependency upon KRas mutations in T58A strains, as well as differential activation of Myc target genes, makes it clear that the context of oncogene expression has a critical role in molecular features of the tumor. Here, we have identified Myc-induced mouse mammary tumors with remarkable similarities to human luminal B tumors and claudin-low tumors. Particularly, the similarities in gene expression, myc target utilization and signaling pathway activation between EMT tumors and claudin-low tumors support the use of this model as a means for experimental study of this molecular subtype of human breast cancer.
MATERIALS AND METHODS
Animal work
All animal work has been conducted according to national guidelines. All mice are from the FVB background. The transgenic mice were generated using the MMTV promoter as previously described. 21 Comparison with the existing MMTV-Myc model 16 was conducted on mice obtained from the Mouse Models of Human Cancer Consortium. Upon genotyping, the transgenic mice were maintained in a constant breeding program to accelerate tumor formation. Tumors were detected through weekly palpation and tumor growth was routinely measured.
RNA and microarray
Preparation of RNA samples from flash frozen tumors was done using the Qiagen (Valencia, CA, USA) RNeasy kit after roto-stator homogenization. RNA from 17 Myc-induced tumors was submitted to the Duke Microarray Core facility for gene expression analysis using Mouse 430A 2.0 Affymetrix (Santa Clara, CA, USA), arrays.
Mutations in KRas were assessed after RT-PCR using Qiagen One-Step RT-PCR with the following primers; 5 0 -GGAGAGAGGCCTGCTGAA and 3 0 -TCTTCTTCCCATCTTTGC TCA. PCR products were gel purified and the samples were sequenced with a nested primer with the following sequence; 5 0 -TAGAAGGCATCGTCAACA C-3 0 .
Western blot analysis
Western blot analysis was conducted using antibodies for Grb2 (Cell Signaling, Danvers, MA, USA, 3972), C-Myc (AbCam, Cambridge, MA, USA, ab32072) and HA-Myc (ABM G036) and HRP-conjugated anti-mouse (BD Biosciences, San Jose, CA, USA, 554002) and anti-rabbit (AbCam ab97051) were used for detection of the specified protein. HA-Myc and C-Myc levels were standardized to Grb2 using image-J software (NIH, Bethesda, MD, USA).
Computational methods
Microarray gene expression data have been submitted to the Gene Expression Omnibus as GSE30805. New gene expression data were combined with previously published mouse gene expression data from GSE15904. In a separate experiment, this combined data set was analyzed with previously published human breast cancer gene expression data sets GSE6532, GSE14020, GSE2034, GSE2603 and GSE4922. Annotation of human breast cancer samples with intrinsic subtypes used previously described methods. 1, 4, 28 All data sets were RMA or MAS5 normalized using Affymetrix Expression Console software depending on the application. When combining data sets, Bayesian factor regression methods were used to remove batch and platform effects. 9, 29 Principle components analysis and plots were generated using Matlab to assess batch and platform removal effects. Unsupervised hierarchical clustering was completed with Cluster 3.0 and results were visualized using Java Tree View (Free Software Foundation Inc., Boston, MA, USA). Significance analysis of microarrays was conducted. 22 The gene lists for Venn diagram using ChIP-Chip Myc target data from 15 and other lists were created by using results from Significance Analysis of Microarrays comparing human mammary epithelial cells that overexpress Myc (GSE3151) and by comparing histological types of Myc-induced tumors. Pathway predictions were conducted as previously described. 9, 21, 23, 30 Specific settings for unsupervised hierarchical clustering, gene signature application and input/ output files are available at https://www.msu.edu/Bandrech1/Supplemental. html. All statistical tests and Kaplan-Meier plots were performed using GraphPad Prism 4 software (La Jolla, CA, USA).
